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Background: Demographic ageing is associated with an increasing number of dementia patients, who reportedly
incur higher costs of care than individuals without dementia. Regarding Germany, evidence on these excess costs is
scarce. Adopting a payer perspective, our study aimed to quantify the additional yearly expenditures per dementia
patient for various health and long-term care services. Additionally, we sought to identify gender-specific cost
patterns and to describe age-dependent cost profiles.
Methods: The analyses used 2006 claims data from the AOK Bavaria Statutory Health Insurance fund of 9,147
dementia patients and 29,741 age- and gender-matched control subjects. Cost predictions based on two-part
regression models adjusted for age and gender and excess costs of dementia care refer to the difference in model-
estimated means between both groups. Corresponding analyses were performed stratified for gender. Finally, a
potentially non-linear association between age and costs was investigated within a generalized additive model.
Results: Yearly spending within the social security system was circa €12,300 per dementia patient and circa €4,000
per non-demented control subject. About two-thirds of the additional expenditure for dementia patients occurred
in the long-term care sector. Within our study sample, male and female dementia patients incurred comparable
total costs. However, women accounted for significantly lower health and significantly higher long-term care
expenditures. Long-term care spending increased in older age, whereupon health care spending decreased. Thus,
at more advanced ages, women incurred greater costs than men of the same age.
Conclusions: Dementia poses a substantial additional burden to the German social security system, with the
long-term care sector being more seriously challenged than the health care sector. Our results suggest that female
dementia patients need to be seen as a key target group for health services research in an ageing society. It seems
clear that strategies enabling community-based care for this vulnerable population might contribute to lowering
the financial burden caused by dementia. This would allow for the sustaining of comprehensive dementia care
within the social security system.
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Dementia disorders are characterized by a progressive loss
of cognitive function accompanied by increasing need for
support in daily life. So far, dementia is incurable, and
pharmacological and non-pharmacological interventions
can only delay its progression [1].
Regarding Germany, about 7.2% of the resident popu-
lation aged 65 and older is estimated to suffer from de-
mentia [2,3]. The risk of developing dementia rises in
older age [2,3], and thus the number of patients is
expected to double to 2.4 million as a result of demo-
graphic ageing by 2050 [4].
About 85% of Germany’s inhabitants are insured
within the social security system, which is characterized
by pay-as-you-go financing, income-dependent but not
risk-dependent insurance contributions and the avail-
ability of long-range health and long-term care services
for a small copayment [5]. In an ageing society, these
principles are associated with a widening gap between
receipts and expenditures. Hence, the interest in quanti-
fying the economic burden of age-associated diseases as
dementia grows.
Within the last 15 years, several studies have estimated
annual per capita expenditures of Statutory Health In-
surance (hereafter SHI) and Compulsory Long-Term
Care Insurance (hereafter LTCI) on patients with Alzhei-
mer’s dementia. To ensure comparability with our own
data referring to 2006 as the base year, we first converted
the reported figures to Euros by applying the average
currency exchange rate of the corresponding year and,
secondly, inflated these figures to 2006 values by apply-
ing the German gross domestic product deflator.
Based on expert interviews, Hallauer and colleagues
calculated circa €15,000 (original value: DM27,500) as
the annual cost of care [6]. By means of patient records,
Schulenburg and collaborators estimated a minimum of
€6,600 if all patients had received community-based care
from relatives and a maximum of €12,400 if all patients
had received institutional care (original values: $8,100
and $15,200) [7]. Kiencke et al. presented a claims data-
based Markov model, indicating costs of circa €13,400
per year survived across different pharmacological treat-
ment groups (original value: €13,100) [8].
Disregarding a comparison with non-demented con-
trol subjects, the cited research left unclear whether de-
mentia per se is linked to an increase in health and
long-term care expenditures.
International studies suggest that dementia patients
incur far higher costs than individuals without dementia
irrespective of the perspective adopted [9-13]. In the
German context, information on these so called excess
costs is scarce. We found one study adopting a societal
perspective [14] and one piece of research adopting the
perspective of the social security system [15].Standardized for the German resident population aged
60 years and older, the latter estimated annual per capita
expenditures of circa €13,300 (original value: €13,800)
for insurants with a dementia diagnosis compared with
circa €3,600 (original value: €3,700) for insurants with-
out such a diagnosis [15]. Around 63% of additional
costs were attributable to LTCI.
Further evidence is needed regarding the contribution
of different health and long-term care services to the
increased spending. Using claims data from a large re-
gional SHI fund for a case–control comparison, this
paper has the threefold objective of:
(1) comparing expenditures for dementia patients and
non-demented control subjects within the distinct
service categories of SHI and LTCI;
(2) searching for potential gender differences
regarding total costs of care and costs within the
distinct service categories; and
(3) analysing age-dependent cost profiles.
Methods
Data source and sample selection
AOK Bavaria is the leading SHI fund in the district of
Middle Franconia covering about 50% of the resident
population aged 65 years and older. For 2005–2007, we
received their complete claims data for all insurants in
this age group. Data provision was carried out according
to German data protection laws, and AOK Bavaria
approved the use of the data set for the intended
analyses.
We restricted our selection process to insurants with
records in all three years born before 1941, leading to a
baseline data set of 151,171 individuals. The allocation
to the case and the control group was based on 2005
and 2006 data, and costs were evaluated for 2006.
We identified people suffering from dementia by con-
structing ‘dementia quarters’, based on inpatient diag-
noses, outpatient diagnoses and anti-dementia drug
prescriptions. Dementia diagnoses included the ICD-10
codes F00, F01, F02, F03 and G30. Anti-dementia drug
prescriptions consisted of donepezil, galantamine, rivas-
tigmine (all ATC code ‘N06DA’) and memantine (ATC
code ‘N06DX01’). In Germany, cholinesterase inhibitors
and memantine are licensed for the treatment of Alzhei-
mer’s dementia only; thus, the prescription of a corre-
sponding drug was seen as on a par with an explicit
diagnosis. Whenever one of these ICD-10 codes and/or
one of these ATC codes was documented at least once
within a quarter, the corresponding quarter was defined
as a dementia quarter.
A total of 14,721 insurants showed dementia quarters.
To increase the validity of diagnoses, we excluded 2,136
individuals with their first documented dementia quarter
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rolled in AOK Bavaria. By this method, 12,040 dementia
patients remained.
Considering the chronic course of dementia, we
required the documentation of at least three dementia
quarters within four consecutive quarters [16,17] to
classify an insurant as an ‘assured dementia case’. At
least one of these dementia quarters had to be in
2006, the year of cost analysis. To avoid loss of infor-
mation, we defined all patients with dementia quarters
who did not fulfil these two requirements as ‘potential
dementia cases’. This process led to 9,147 patients
with assured dementia (case group) and 2,893 patients
with potential dementia. The latter were included in a
sensitivity analysis.
From the remaining subjects without dementia quarters
(n= 136,450), we dropped 1,122 individuals with pira-
cetam prescriptions. Treatment with piracetam is com-
mon in dementia disorders, but it is not an exclusively
dementia-specific medication. We could not control for
the consumption of ginkgo biloba because SHI reimburse-
ment is limited for these pharmaceuticals, and therefore
they are usually paid out-of-pocket.
Age- and gender-matched control subjects to the as-
sured dementia patients were randomly selected from
the 135,328 potential control subjects in a 4:1 ratio. As
the dementia prevalence in men aged 84 onwards and in
women aged 82 onwards exceeded 20%, an exact 4:1
matching was not feasible. For these age groups, we
included all remaining potential control subjects, and
the eventual control group contained 29,741 individuals.
The inclusion criteria for our study sample are sum-
marized below:(1) Aged at least 65 years on 1 January 2006.
(2) Continuously insured with AOK Bavaria in 2005
and 2006.
(3) Case group(a) At least three dementia quarters within four
consecutive quarters of 2005 and 2006
(b) At least one dementia quarter in 2006(4) Control group
(a) No dementia quarter in 2005 and 2006
(b) No piracetam prescription in 2005 and 2006Costs of care
The German social security system provides health in-
surance, long-term care insurance, pension insurance,
(occupational) accident insurance and unemployment
insurance. Payments of the last two benefits are dis-
pensed with on retirement, and the amount of retire-
ment pay is not affected by health status. Thus, costdifferences in the health and long-term care sector are
an acceptable base on which to estimate excess expendi-
tures for dementia patients within the social security sys-
tem [15].Background information on SHI
SHI covers hospital care, ambulatory treatment by gen-
eral practitioners and medical specialists, medication
(except for drugs paid out-of-pocket), medically indi-
cated non-physician services and medical aids, home
health care and rehabilitation. SHI spending equals the
sum of 2006 expenditures for these services.
Whenever a treatment took place only partly in
2006, we calculated treatment duration within the ob-
servation period. Then, costs were attributed propor-
tionally to the time of resource use, implying constant
amounts per day.
Physician services are billed via a fee for service system
that settles a specific score for each service. The monet-
ary value of services is calculated by multiplying this
score by a quarter- and specialization-specific point
value. We converted the scores into Euro amounts by
applying the corresponding monetary point values pub-
lished by the Association of SHI Physicians of Bavaria.
The medication category includes all prescribed drugs.
The corresponding pharmacy retail prices are available
from the Scientific Institute of the AOK. However, phar-
macies distribute not only drugs but also to some extent
medical aids (e.g. blood pressure meters, blood glucose
meters or bandages), which also occur under the head-
ing medication because of accounting rules.
Hospitals provide inpatient treatment, emergency care
and outpatient services (e.g. day surgery, preadmission
services, post-discharge services), which are for the most
part reimbursed via a diagnosis-specific fixed remuner-
ation additionally weighted by the patient’s comorbidity
status (Diagnosis Related Group, DRG). Overall spend-
ing is explicitly documented in the claims data.
The expenditures for non-physician services and home
health care reported in the claims data refer to prescrip-
tions. A prescription for non-physician services covers a
fixed number of treatment sessions, whereas home
health care is limited to a distinct time horizon. The ab-
solute payment amount per prescription depends first
on the number of contacts between patient and provider
and second on the type of services provided. These
details on intensity of resource utilization are not trace-
able; instead, only the total sum accrued for the deliv-
ered services is reported.Background information on LTCI
Despite being designed as an individual social insurance
branch, LTCI is managed under one umbrella with SHI.
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to physical impairment and supports various community-
based and institutional long-term care services.
The Code of Social Law defines three care levels, each
connected to a fixed monthly tariff for community-
living or institutionalized beneficiaries. These payments
represent supplementary financial support and are not
intended to provide full coverage of costs incurred for
long-term care. In order to profit from LTCI services,
an application is required followed by an appraisal from
the Medical Review Board of the SHI Funds.
To quantify per capita costs within the social security
system, we added LTCI and SHI expenditures and la-
belled the sum costs of formal care.Statistical analysis
For a first impression, we compared unadjusted mean
per capita expenditures for dementia patients and
non-demented control subjects using Wilcoxon tests,
which account for the highly skewed distribution of
cost data.
Our primary analysis adjusted for the covariates age
and gender. It applied generalized linear models (here-
after GLM) assuming a gamma distribution with log
link. Cost differences were evaluated via two different
approaches: approach 1 for categories in which costs
were incurred by almost every patient and approach 2
for categories with a user quota below 90%.
In approach 1, a one-step GLM adjusted for age and
gender was performed to estimate annual per capita
expenditures for cases and control subjects. We assigned
a small positive value to the few individuals without
costs to avoid their exclusion from the analyses. Ap-
proach 1 was used for the domains general practitioner,
medication, SHI expenditures and costs of formal care.
For the categories medical specialist, hospital treat-
ment, non-physician services, medical aids, home health
care, rehabilitation and long-term care services, we fol-
lowed approach 2, in which we calculated two-part re-
gression models [18]. Part 1 estimated the probability of
positive expenditures based on logistic regression. In
part 2, a gamma model, as described above, was applied
to estimate the annual amount of expenditures for those
with positive expenditures. Both stages included age and
gender as covariates. To derive per capita costs, the es-
timated probabilities for positive expenditures were
multiplied by the predicted costs per user. Recycled pre-
dictions with dementia as the coefficient of interest were
used to investigate differences between the case and the
control group combined for both stages [19]. In this ap-
proach, two predictions are derived based on the regres-
sion estimates: first, assuming all subjects do not have
dementia; second, assuming that all have dementia. Themean differences between these predictions are the ex-
cess costs of dementia adjusted for covariates [20].
Adjusted SHI expenditures and adjusted costs of for-
mal care as per the regression model differed slightly
from the sum of adjusted mean costs in the distinct cat-
egories, which results from the stepwise calculation
within the two-part model (approach 2). Moreover, the
two-part model provided two p-values, the first referring
to differences in the probability of service use, and the
second referring to cost differences among service users.
We assumed a significant difference at the patient level
if both parts pointed in the same direction and if at least
one of the two p-values was significant.
We also tested an extended model which considered
all possible single interaction terms between gender, age
and dementia. Cost estimations were comparable, but
the interpretation of p-values would have been less
straightforward. Thus, we chose the simple model with-
out interaction terms.
Excess costs of dementia care were obtained by sub-
tracting the estimated costs per control subject from the
estimated costs per case [21]. For total costs, we calcu-
lated the 95% confidence interval of adjusted costs based
on 1,000 nonparametric bootstrap replications.
Supplementary to the primary analysis, we performed
two sensitivity analyses. Sensitivity analysis 1 defined de-
mentia less strictly and included the 2,893 potential
cases. In sensitivity analysis 2, the regression models
considered dummy variables for specific comorbid con-
ditions and death in 2007. We included the five most
common comorbidities from the complex ‘cardiovascu-
lar and metabolic disorders’ [22], which were hyperten-
sion (ICD I10–I15), lipid metabolism disorder (ICD
E78), diabetes mellitus (ICD E10–E14), chronic ischae-
mic heart disease (ICD I20, I21, I25) and cardiac insuffi-
ciency (ICD I50). An insurant was considered to suffer
from the respective disease if a corresponding ICD was
coded at least once in 2006.
As a secondary analysis, we investigated gender differ-
ences regarding costs of care, within a stratified model.
Again, recycled predictions were calculated, this time
with gender as the coefficient of interest. Here, the inter-
action term ‘dementia*gender’ was also included in the
previously described GLMs. Further interactions were
disregarded, which enables an isolated observation of
the gender effect in the case and in the control group.
Within a tertiary analysis, we evaluated a possible
non-linear association between age and costs of formal
care, SHI expenditures and LTCI expenditures. We
therefore fitted a generalized additive model allowing a
separate smooth function of age for the four subgroups
of male control subjects, female control subjects, male
cases and female cases. The smooth functions were esti-
mated using thin plate regression splines, and smoothing
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validation [23].
A significance level of 5% was used for all analyses,




According to Table 1, dementia patients were around
2 years older than control subjects and had a higher
share of females because of the imperfect matching.
After adjustment for these demographic differences,
they still depended to a larger percentage on professional
long-term care and were more likely to die within the
year following the observation.
The potential dementia patients who were disregarded
within the matching algorithm were younger and had a
lower female quota than the cases and control subjects.
Regarding the other baseline characteristics, they ranged
between both groups with a slight tendency towards the
case group.
Diabetes and heart diseases were more prominent in
dementia patients but hypertension and lipid metabol-
ism disorder in control subjects.
Expenditures within the case and the control group
Costs of care and excess expenditures
The comparison of unadjusted means yielded annual
expenditures of circa €12,600 for dementia patients and
circa €4,000 for non-demented control subjects. As
highlighted in Figure 1, costs for dementia patients were
increased for all categories except medical specialists.
Apart from rehabilitation, all observed differences were
significant.Table 1 Baseline characteristics of the study sample
Characteristics of the study sample Dementia patients Non
N 9,147
Mean age 81.6 (7.4)
Females (as a %) 6,819 (74.6%)
Beneficiary of long-term care (as a %) 6,037 (66.0%)
Community-living at 1 January 2006 (as a %) 6,212 (67.9%)
Shift to nursing home within 2006 (as a %) 654 (7.1%)
Death in 2007 (as a %) 1,621 (17.7%)
Hypertension 5,768 (63.1%)
Lipid metabolism disorder 2,718 (29.7%)
Diabetes mellitus 3,446 (37.7%)
Ischaemic heart disease 2,747 (30.0%)
Congestive heart failure 3,075 (33.6%)
Data are mean (standard deviation) unless noted otherwise.
* Statistical significance at 5% level based on Chi2 tests for categorical variables and
~ Statistical significance at 5% level adjusted for age and gender within logistic regTable 2 summarizes the model-based cost estimates
adjusting for age and gender differences in both groups.
In this primary analysis, annual costs of formal care were
circa €12,300 in the case group and almost equally dis-
tributed between SHI and LTCI. In the control group,
the corresponding ratio was around 80:20, totalling an-
nual expenditures of circa €4,000.
Focusing on the distinct categories itemised in
Table 2, dementia patients incurred consistently higher
spending than control subjects. The difference was not
significant in the use of medical specialists. Total SHI
expenditures were increased by circa 80% and LTCI
expenditures by circa 700%. Around two-thirds of the
excess expenditures on formal care were attributable to
LTCI.
Table 3 illustrates how differences in per capita
expenditures came about: first, except for rehabilita-
tion, the probability of service use was significantly
increased in dementia patients (p1). Second, the aver-
age spending on service users with dementia was in
general remarkably higher than the average spending
on service users without dementia (p2). Regarding
medical specialists, the probability of service utilization
and costs per user pointed in opposite directions. This
resulted in an insignificant difference at the per capita
level.Sensitivity analyses
Including potential dementia cases in sensitivity analysis
1 only affected cost estimates within the case group.
Compared with the primary analysis, SHI expenditures
decreased by circa €200 and LTCI expenditures by circa
€700. Altogether, annual costs of formal care were esti-
mated as circa €11,400 (primary analysis: circa €12,300).-demented control subjects p-value* Potential dementia cases
29,741 2,893
79.6 (6.4) <0.0001 79.0 (7.7)
20,932 (70.4%) <0.0001 2,020 (69.8%)
3,829 (12.9%) <0.0001 1,078 (37.3%)
29,028 (97.7%) <0.0001 2,484 (85.9%)
292 (1.0%) <0.0001 107 (3.7%)
1,764(5.9%) <0.0001 311 (10.8%)
19,109 (64.3%) 0.04 1,881 (65.0%)
10,825 (36.4%) <0.0001 967 (33.4%)
8,977 (30.2%) <0.0001 1,014 (35.1%)
8,027 (27.0%) <0.0037 836 (28.9%)
6,478 (21.8%) <0.0001 750 (25.9%)






























Non-demented Control Dementia Patient
Health Insurance Services
Figure 1 Unadjusted mean expenditures per year for dementia patients and non-demented control subjects.
Table 2 Annual per capita costs (€) and estimated excess costs (€) adjusted for age and gender
Service component Cost per dementia
patient (n = 9,147)
Cost per non-demented





Costs of formal care * [95%-CI] 12,343 [12,126; 12,572] 4,034 [3,957; 4,109] 8,309
[8,081; 8,552]
Health insurance expenditures* 5,813 3,256 2,557
Medication 1,312 671 641
including anti-dementia drugs (two-step) 119 0 119
General practitioner 641 367 274
Approach 2
two-step-model
Medical specialist 432 429 3
Hospital treatment 2,237 1,325 912
Non-physician services 199 83 116
Medical aids 339 106 233
Home health care 361 138 223
Rehabilitation 164 150 14
Long-term care services 6,353 797 5,556
Data are means based on recycled predictions with dementia as the coefficient of interest.
The 95% confidence interval is based on 1,000 nonparametric bootstrap replications.
* Results of model estimation; the addition of mean costs per category yields slightly different figures.
** Defined as the difference of estimated means within both subgroups.
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Table 3 Probability of service use and annual costs per user adjusted for age and gender
Service component Dementia patients (n = 9,147) Non-demented control
















Costs of formal care* 100.0 12,343 96.5 4,034 / <0.0001
Health insurance
expenditures*
100.0 5,813 96.4 3,256 / <0.0001
Medication 99.5 1,312 93.5 671 / <0.0001
including anti-dementia
drugs (two-step)
15.2 764 0.0 0
General practitioner 99.4 641 93.7 367 / <0.0001
Approach 2
two-part model
Medical specialist 81.4 517 81.0 524 0.0009 0.47
Hospital treatment 42.5 5,504 28.2 4,697 <0.0001 <0.0001
Non-physician services 27.0 720 21.6 390 <0.0001 <0.0001
Medical aids 65.2 538 35.6 293 <0.0001 <0.0001
Home health care 17.0 2,254 6.3 2,118 <0.0001 0.14
Rehabilitation 4.8 3,416 4.8 3,135 0.9 0.0036
Long-term care services 66.0 9,918 12.9 5,483 <0.0001 <0.0001
Data derive from one-step and two-step Generalized Linear Models with dementia as the coefficient of interest.
Significance at the patient level is estimated based on p1 and p2 in the two-part models and based on p2 in the one-step models.
p1 derives from the logistic model (approach 2, step 1) and p2 derives from the gamma model (approach 2, step 2 and approach 1).
* Results of model estimation; the addition of mean costs per category yields slightly different figures.
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again revealed annual costs of formal care of circa
€12,300 in dementia patients and circa €4,100 (primary
analysis: circa €4,000) in non-demented control subjects.
The excess expenditures for dementia patients were
comparable to the primary analysis.Gender-specific cost profiles
Costs of care and excess expenditures for dementia patients
according to gender
Similar to the primary analysis, the gender-stratified
GLM revealed significant cost differences between male
cases and male control subjects as well as between fe-
male cases and female control subjects regarding all ser-
vice categories except medical specialists (results not
shown).
Adjusted for age, annual costs of formal care
amounted to circa €12,600 in male dementia patients
and circa €4,300 in male control subjects. The corre-
sponding figures observed in females were slightly lower
with circa €12,200 in dementia patients and circa €3,900
in non-demented control subjects.
Compared with control subjects, male dementia
patients incurred circa €5,300 extra in LTCI (circa
€5,900 vs. circa €600) and circa €2,900 extra in SHI
(circa €6,500 vs. circa €3,600). The excess expenditures
for female dementia patients compared with female con-
trol subjects amounted to circa €5,600 in LTCI (circa€6,500 vs. circa €900) and circa €2,500 in SHI (circa
€5,600 vs. circa €3,100).
Gender-specific cost profiles
The gender-specific cost compilation within the case
group is described in Table 4. Male dementia patients in-
curred significantly higher SHI spending (circa €6,500
vs. circa €5,600), and female dementia patients incurred
significantly higher LTCI spending (circa €6,500 vs. circa
€5,900). The effects in the opposite direction led to com-
parable total costs of formal care (p = 0.17).
Within SHI, spending on home health care and med-
ical aids was remarkably increased in female dementia
patients, but male dementia patients incurred substan-
tially higher expenditures regarding medical specialists,
hospital treatment and non-physician services. Expendi-
tures for rehabilitation, general practitioners, medication
in general as well as for anti-dementia drugs in particu-
lar did not differ.
Within the control group, we also observed increased
SHI expenditures in men and increased LTCI expendi-
tures in women. Here, the comparably low LTCI expen-
ditures failed to balance spending within both branches,
leading to higher costs of formal care for men (results
not shown).
Age-dependent cost profiles
Costs of formal care for dementia patients and control
subjects increased with age. This effect was driven by
Table 4 Gender-specific annual mean expenditures within the case group adjusted for age
























100.0 12,648 12,648 100.0 12,209 12,209 / 0.17
Health insurance
expenditures*
100.0 6,465 6,465 100.0 5,558 5,558 / 0.002
Medication 99.4 1,394 1,394 99.5 1,277 1,277 / 0.12
including anti-
dementia drugs
18.8 782 127 14.0 770 115 0.12 0.70






88.2 675 595 79.1 447 363 <0.0001 <0.0001
Hospital
treatment
46.3 5,959 2,790 41.0 5,308 2,157 0.0005 0.01
Non-physician
services
28.3 839 225 26.5 677 190 0.25 0.03
Medical aids 56.9 508 301 68.8 534 349 <0.0001 0.05
Home health
care
14.3 1,761 266 17.9 2,461 392 <0.0001 <0.0001
Rehabilitation 5.2 3,307 170 4.6 3,459 164 0.81 0.21
Long-term
care services*
59.3 9,027 5,935 68.3 10,267 6,467 0.065 <0.0001
Per user data derive from one-step and two-step Generalized Linear Models with gender as the coefficient of interest.
Patient level data are means based on recycled predictions with gender as the coefficient of interest.
Significance at the patient level is estimated based on p1 and p2 in the two-part models and based on p2 in the one-step models.
p1 derives from the logistic model (approach 2, step 1) and p2 derives from the gamma model (approach 2, step 2 and approach 1).
* Results of model estimation; the addition of mean costs per category yields slightly different figures.
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currently, as plotted in Figure 2.
Owing to increasing LTCI expenditures, costs of for-
mal care for females exceeded costs for males at more
advanced age, which affected cases about 10 years earlier
than control subjects.
Within both genders, the differences in SHI expendi-
tures, LTCI expenditures and costs of formal careFigure 2 Age-dependent cost profiles for health care, long-term carebetween dementia patients and non-demented control
subjects reduced slightly in older age.
In general, the impact of age on the three cost out-
comes was highly significant (p< 0.0001) within all four
subgroups. The only exceptions were borderline signifi-
cance regarding costs of formal care in male dementia
patients (p = 0.06) and insignificance regarding costs per
LTCI user in male control subjects (p = 0.99).and formal care.
Table 5 Impact of various covariates on the costs of care
Variable Costs of formal care Long-term care insurance Health insurance
Probability of use Costs per user expenditures
Impact p-value* Impact p-value* Impact p-value* Impact p-value*
Dementia 2.84 <0.0001 16.85 <0.0001 1.87 <0.0001 1.71 <0.0001
Age~ 1.19 <0.0001 3.64 0.003 1.10 <0.0001 1.05 <0.0001
Female gender 0.93 0.37 1.12 <0.0001 1.17 <0.0001 0.86 <0.0001
Age*female gender~ 1.21 <0.0001 1.6 <0.0001 1.07 0.008 1.05 0.01
Age*dementia~ 0.83 <0.0001 0.47 <0.0001 0.95 0.03 0.78 <0.0001
Female gender*dementia 1.12 0.0006 0.98 0.73 0.98 0.56 1.08 0.02
* p-values are derived from Generalized Linear Models (assuming a gamma distribution for costs and a binomial distribution for the probability of use).
~ Effects are reported per decade.
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ity to death and comorbidity in the model.
To better understand the interactions between various
covariates, we reverted to the extended model with inter-
action terms. As documented in Table 5, the age-
dependent cost profiles of women progressed more
steeply than those of men (impact of ‘age*female gender’
>1). Moreover, the age-dependent cost trend was less
pronounced within the case group (impact of
‘age*dementia’ <1) but, apart from long-term care, the
dementia diagnosis affected the curves of female patients
more severely than those of male patients (impact of ‘fe-
male gender*dementia’ >1).
Discussion
Adopting the perspective of the German social security
system, our primary analysis revealed annual per capita
costs for dementia patients of circa €12,300. This is in
good agreement with previous national estimates based
on patient-level data [7,8,15].
Dementia patients were approximately three times
more expensive than non-demented control subjects.
They incurred excess costs of around €8,300, about two-
thirds of which occurred in the long-term care sector.
Compared with the BARMER GEK report (SHI: circa +
€3,700; LTCI circa + €6,100) [15], we calculated the add-
itional burden more conservatively, which might be
explained by the older age structure of our sample com-
bined with our finding that excess expenditures decline
with older age. The figures from the AgeCoDe study
(medical care: circa + €3,000; professional long-term
care: circa + €9,400) [14] include out-of-pocket pay-
ments, rendering a direct comparison unfeasible.
Given a female majority among dementia patients
[2,16], the women’s cost profile influences the cost struc-
ture of the entire population. Within the general older
population, previous research observed significantly less
spending on ‘acute medical services’ combined with sig-
nificantly higher spending on ‘durable supportive ser-
vices’ in females [24,25]. The latter is probably becauseolder women are more likely to live alone than men of
the same age and might thus have less access to informal
care: older men perhaps still live with a (slightly
younger) spouse who can act as an informal caregiver,
whereas older women are more often widowed. Owing
to the longer life expectancy of females, the living situ-
ation described is especially pronounced among the old-
est of the old. Moreover, women were found to develop
a comparable level of disability about 10 years earlier
than men [25], which seems to be a further aspect lead-
ing to their increased usage of formal care services. Our
secondary analysis validated this gender-specific cost
compilation for individuals with dementia.
The cost profiles of the tertiary analysis revealed a
continuous increase in LTCI spending accompanied by
decreasing SHI expenditures in older age. The increase
in LTCI spending overcompensates for the decline in
SHI spending by a long way; thus, it seems obvious that
demographic ageing affects the organization of long-
term care services more seriously than the organization
of health care services.
An interesting subsidiary finding of the tertiary ana-
lysis was the steadily declining SHI profile of dementia
patients, which contradicted the expected inverse u-
shape [26]. This picture might reflect a reduced ability
of individuals with dementia to communicate their
health care needs adequately [27] or even denote that
expensive or interactive treatment strategies are not con-
sidered worthwhile in this population.
We are aware that our results need to be interpreted
cautiously because of some methodological restrictions.
We did not adjust for comorbidity because we
assumed a direct connection between dementia and the
occurrence of several comorbid conditions and their re-
spective treatment costs [11,28,29]. Including comorbid-
ity as an additional confounder might have covered this
specific impact of dementia on existing comorbid condi-
tions. This decision seems not to result in remarkable
bias as the comorbidity-adjusted sensitivity analysis
yielded comparable results.
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gression models to avoid overadjustment as a dementia
diagnosis is a strong predictor for nursing home place-
ment [30-32]. The overall care strategies probably differ
between community setting and institutional setting,
which implies a setting-specific compilation of services.
Moreover, claims data as the single source of informa-
tion imply specific advantages and disadvantages [33].
The accuracy of diagnoses remains uncertain, and the
agreement of different data sources is insufficient
regarding dementia disorders [34-37]. Requiring mul-
tiple dementia indicators enhances the validity of case
group assignment but also selects more severe cases,
whereas relying on one single indication implies a
higher risk of false-positive classification. We consider
our strategy to distinguish assured and potential de-
mentia patients as a practicable solution, and suppose
the ‘true’ excess costs of dementia care to lie in be-
tween the results of both analyses (circa €8,300 vs. circa
€7,400). However, our approach regarded a minimum
of three anti-dementia drug prescriptions within four
consecutive quarters as on a par with a minimum of
three dementia diagnoses in the corresponding period.
By this method, we included 149 individuals (1.6%) who
never received a dementia diagnosis despite it might
have been more precise to assume mild cognitive im-
pairment instead of manifest dementia in these cases.
Given the low percentage, we desisted from excluding
the individuals concerned.
Moreover, claims data lack information on disease se-
verity. Thus, the impact of disease progression on costs
[38] could not be accounted for despite the cost impact
of disease severity is well documented especially in the
field of long-term care [6,14,39]. Educational level, eco-
nomic situation and family status are also only traceable
rudimentarily from claims data, but the association be-
tween these variables and service utilization is broadly
accepted. For example, living alone is a predictor for
long-term care expenditures, because single people are
presumed to have less access to informal support and
therefore assumed to rely to a larger extent on profes-
sional help [40].
On the other hand, relying on claims data prevents the
disregarding of considerable parts of the effective patient
clientele. Observational studies and clinical trials based
on primary information often do not address frail and
institutionalized individuals. In contrast, claims data ac-
count for all insurants irrespective of health status and
living environment and are thus less selective.
To ensure sound decision making, unambiguous eco-
nomic information for the payer is paramount. Cost in-
formation from claims data are basically reliable,
because they report the de facto spending on a broad
range of medical and non-medical services. Thus,defining unit costs and extrapolating self-reported data
becomes dispensable. The accuracy of such estimates is
unclear, because assuming the recall period to be repre-
sentative of the entire observation period seems ques-
tionable, and self-reported service utilization may be
impaired by recall bias [41].
Regarding the future organization of dementia care,
it must not be forgotten that, despite not being
accounted for within a payer perspective, informal care
is the crucial expense factor [14,39,42], especially in
the community setting. The number of potential family
caregivers will decrease because of changing living
arrangements, increasing women in the labour force
and decreasing birth rates in industrialized countries.
Thus, a shift from informal towards formal care and a
rising economic burden for social security systems can
be expected all round the world. Our data provide in-
formation on the age- and gender-specific health and
long-term care needs of individuals with dementia.
This knowledge is a suitable starting point for develop-
ing targeted programmes to manage future care for
this clientele efficiently.
Conclusions
Our data suggest a special need to regard female demen-
tia patients as a crucial target group. Owing to longer
life expectancy, women face an increased risk of devel-
oping dementia. Moreover, females rely earlier and to a
larger extent on professional long-term care than males.
Dementia leads in turn to a comparatively early depend-
ency on long-term care services. These services are the
crucial expense factor in dementia care, and the corre-
sponding expenditures rise steeply with age. Altogether,
innovative strategies fostering community-based long-
term care for females with dementia can influence the
key driver of the financial burden resulting from demen-
tia disorders. This would help to sustain a socially ac-
ceptable financing of comprehensive dementia care
within the social security system.
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